ABEO Abeona Therapeutics Inc.

7.96
-0.22  -3%
Previous Close 8.18
Open 8.2
Price To Book 2.85
Market Cap 382818911
Shares 48,092,828
Volume 978,141
Short Ratio
Av. Daily Volume 399,118

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 ongoing as of December 6, 2018.
ABO-101
Sanfilippo syndrome type B (MPS IIIB)
Phase 3 trial to be initiated mid-2019.
EB-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 safety and tolerability data to be presented at WORLDSymposium February 6, 2019.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)

Latest News

  1. Is Abeona Therapeutics's (NASDAQ:ABEO) 173% Share Price Increase Well Justified?
  2. Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
  3. Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
  4. Edited Transcript of ABEO earnings conference call or presentation 19-Mar-19 2:00pm GMT
  5. Abeona Therapeutics Inc (ABEO) Q4 2018 Earnings Conference Call Transcript
  6. Abeona Therapeutics: 4Q Earnings Snapshot
  7. Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  8. What Investors Should Know About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Financial Strength
  9. Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference
  10. New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
  11. Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer
  12. The Unknown Biotech Play that Could Deliver 400% Returns, or Much More
  13. Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
  14. Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
  15. How Should Investors Feel About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) CEO Pay?
  16. Is Abeona Therapeutics Inc (ABEO) A Good Stock To Buy?
  17. Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
  18. Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
  19. Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day
  20. Moving Average Crossover Alert: Abeona Therapeutics